{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T15:28:54Z","timestamp":1789140534410,"version":"build-2803163510"},"reference-count":161,"publisher":"Aging and Disease","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aging and disease"],"published-print":{"date-parts":[[2025]]},"DOI":"10.14336\/ad.2025.0189","type":"journal-article","created":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T23:20:31Z","timestamp":1744154431000},"page":"0","source":"Crossref","is-referenced-by-count":6,"title":["Mitochondrial Imbalance in Down Syndrome: A Driver of Accelerated Brain Aging?"],"prefix":"10.14336","author":[{"given":"Xinxin","family":"Zuo*","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"5462","reference":[{"key":"key-10.14336\/AD.2025.0189-1","doi-asserted-by":"crossref","unstructured":"Zong Y, Li H, Liao P, Chen L, Pan Y, Zheng Y, et al. (2024). Mitochondrial dysfunction: mechanisms and advances in therapy. Signal Transduct Target Ther, 9:124.","DOI":"10.1038\/s41392-024-01839-8"},{"key":"key-10.14336\/AD.2025.0189-2","doi-asserted-by":"crossref","unstructured":"Bustamante-Barrientos FA, Luque-Campos N, Araya MJ, Lara-Barba E, de Solminihac J, Pradenas C, et al. (2023). Mitochondrial dysfunction in neurodegenerative disorders: Potential therapeutic application of mitochondrial transfer to central nervous system-residing cells. J Transl Med, 21:613.","DOI":"10.1186\/s12967-023-04493-w"},{"key":"key-10.14336\/AD.2025.0189-3","doi-asserted-by":"crossref","unstructured":"Perrone L (2023). Editorial: Mitochondrial dysfunction as a target in neurodegenerative diseases. Front Mol Neurosci, 16:1271175.","DOI":"10.3389\/fnmol.2023.1271175"},{"key":"key-10.14336\/AD.2025.0189-4","doi-asserted-by":"crossref","unstructured":"Rueda Revilla N and Martinez-Cue C (2020). Antioxidants in Down Syndrome: From Preclinical Studies to Clinical Trials. Antioxidants(Basel), 9.","DOI":"10.3390\/antiox9080692"},{"key":"key-10.14336\/AD.2025.0189-5","doi-asserted-by":"crossref","unstructured":"Baburamani AA, Patkee PA, Arichi T and Rutherford MA (2019). New approaches to studying early brain development in Down syndrome. Dev Med Child Neurol, 61:867-879.","DOI":"10.1111\/dmcn.14260"},{"key":"key-10.14336\/AD.2025.0189-6","doi-asserted-by":"crossref","unstructured":"Bayona-Bafaluy MP, Garrido-Perez N, Meade P, Iglesias E, Jimenez-Salvador I, Montoya J, et al. (2021). Down syndrome is an oxidative phosphorylation disorder. Redox Biol, 41:101871.","DOI":"10.1016\/j.redox.2021.101871"},{"key":"key-10.14336\/AD.2025.0189-7","unstructured":"Head E, Powell D, Gold BT and Schmitt FA (2012). Alzheimer's Disease in Down Syndrome. Eur J Neurodegener Dis, 1:353-364."},{"key":"key-10.14336\/AD.2025.0189-8","doi-asserted-by":"crossref","unstructured":"Wiseman FK, Al-Janabi T, Hardy J, Karmiloff-Smith A, Nizetic D, Tybulewicz VL, et al. (2015). A genetic cause of Alzheimer disease: mechanistic insights from Down syndrome. Nat Rev Neurosci, 16:564-74.","DOI":"10.1038\/nrn3983"},{"key":"key-10.14336\/AD.2025.0189-9","doi-asserted-by":"crossref","unstructured":"Tan KL, Lee HC, Cheah PS and Ling KH (2023). Mitochondrial Dysfunction in Down Syndrome: From Pathology to Therapy. Neuroscience, 511:1-12.","DOI":"10.1016\/j.neuroscience.2022.12.003"},{"key":"key-10.14336\/AD.2025.0189-10","doi-asserted-by":"crossref","unstructured":"Perluigi M, Di Domenico F and Buttterfield DA (2014). Unraveling the complexity of neurodegeneration in brains of subjects with Down syndrome: insights from proteomics. Proteomics Clin Appl, 8:73-85.","DOI":"10.1002\/prca.201300066"},{"key":"key-10.14336\/AD.2025.0189-11","doi-asserted-by":"crossref","unstructured":"Ganguly BB and Kadam NN (2023). Therapeutics for mitochondrial dysfunction-linked diseases in Down syndrome. Mitochondrion, 68:25-43.","DOI":"10.1016\/j.mito.2022.11.003"},{"key":"key-10.14336\/AD.2025.0189-12","doi-asserted-by":"crossref","unstructured":"Helguera P, Seiglie J, Rodriguez J, Hanna M, Helguera G and Busciglio J (2013). Adaptive downregulation of mitochondrial function in down syndrome. Cell Metab, 17:132-40.","DOI":"10.1016\/j.cmet.2012.12.005"},{"key":"key-10.14336\/AD.2025.0189-13","doi-asserted-by":"crossref","unstructured":"Gensous N, Bacalini MG, Franceschi C and Garagnani P (2020). Down syndrome, accelerated aging and immunosenescence. Semin Immunopathol, 42:635-645.","DOI":"10.1007\/s00281-020-00804-1"},{"key":"key-10.14336\/AD.2025.0189-14","doi-asserted-by":"crossref","unstructured":"Lopez-Otin C, Blasco MA, Partridge L, Serrano M and Kroemer G (2023). Hallmarks of aging: An expanding universe. Cell, 186:243-278.","DOI":"10.1016\/j.cell.2022.11.001"},{"key":"key-10.14336\/AD.2025.0189-15","doi-asserted-by":"crossref","unstructured":"Tayebati SK, Cecchi A, Martinelli I, Carboni E and Amenta F (2019). Pharmacotherapy of Down's Syndrome: When and Which? CNS Neurol Disord Drug Targets, 18:750-757.","DOI":"10.2174\/1871527318666191114092924"},{"key":"key-10.14336\/AD.2025.0189-16","doi-asserted-by":"crossref","unstructured":"Peng L, Baradar AA, Aguado J and Wolvetang E (2023). Cellular senescence and premature aging in Down Syndrome. Mech Ageing Dev, 212:111824.","DOI":"10.1016\/j.mad.2023.111824"},{"key":"key-10.14336\/AD.2025.0189-17","doi-asserted-by":"crossref","unstructured":"Kozlov G, Franceschi C and Vedunova M (2024). Intricacies of aging and Down syndrome. Neurosci Biobehav Rev, 164:105794.","DOI":"10.1016\/j.neubiorev.2024.105794"},{"key":"key-10.14336\/AD.2025.0189-18","doi-asserted-by":"crossref","unstructured":"Horvath S, Garagnani P, Bacalini MG, Pirazzini C, Salvioli S, Gentilini D, et al. (2015). Accelerated epigenetic aging in Down syndrome. Aging Cell, 14:491-5.","DOI":"10.1111\/acel.12325"},{"key":"key-10.14336\/AD.2025.0189-19","doi-asserted-by":"crossref","unstructured":"Aivazidis S, Coughlan CM, Rauniyar AK, Jiang H, Liggett LA, Maclean KN, et al. (2017). The burden of trisomy 21 disrupts the proteostasis network in Down syndrome. PLoS One, 12:e0176307.","DOI":"10.1371\/journal.pone.0176307"},{"key":"key-10.14336\/AD.2025.0189-20","doi-asserted-by":"crossref","unstructured":"Bordi M, Darji S, Sato Y, Mellen M, Berg MJ, Kumar A, et al. (2019). mTOR hyperactivation in Down Syndrome underlies deficits in autophagy induction, autophagosome formation, and mitophagy. Cell Death Dis, 10:563.","DOI":"10.1038\/s41419-019-1752-5"},{"key":"key-10.14336\/AD.2025.0189-21","doi-asserted-by":"crossref","unstructured":"Isaev NK, Genrikhs EE, Oborina MV and Stelmashook EV (2018). Accelerated aging and aging process in the brain. Rev Neurosci, 29:233-240.","DOI":"10.1515\/revneuro-2017-0051"},{"key":"key-10.14336\/AD.2025.0189-22","unstructured":"Down JL (1995). Observations on an ethnic classification of idiots. 1866. Ment Retard, 33:54-6."},{"key":"key-10.14336\/AD.2025.0189-23","unstructured":"Lejeune J, Gautier M and Turpin R (1959). [Study of somatic chromosomes from 9 mongoloid children]. C R Hebd Seances Acad Sci, 248:1721-2."},{"key":"key-10.14336\/AD.2025.0189-24","unstructured":"Gardiner K and Davisson M (2000). The sequence of human chromosome 21 and implications for research into Down syndrome. Genome Biol, 1:REVIEWS0002."},{"key":"key-10.14336\/AD.2025.0189-25","doi-asserted-by":"crossref","unstructured":"Epstein CJ, Avraham KB, Lovett M, Smith S, Elroy-Stein O, Rotman G, et al. (1987). Transgenic mice with increased Cu\/Zn-superoxide dismutase activity: animal model of dosage effects in Down syndrome. Proc Natl Acad Sci U S A, 84:8044-8.","DOI":"10.1073\/pnas.84.22.8044"},{"key":"key-10.14336\/AD.2025.0189-26","unstructured":"Davisson MT, Schmidt C and Akeson EC (1990). Segmental trisomy of murine chromosome 16: a new model system for studying Down syndrome. Prog Clin Biol Res, 360:263-80."},{"key":"key-10.14336\/AD.2025.0189-27","doi-asserted-by":"crossref","unstructured":"Lyle R, Gehrig C, Neergaard-Henrichsen C, Deutsch S and Antonarakis SE (2004). Gene expression from the aneuploid chromosome in a trisomy mouse model of down syndrome. Genome Res, 14:1268-74.","DOI":"10.1101\/gr.2090904"},{"key":"key-10.14336\/AD.2025.0189-28","doi-asserted-by":"crossref","unstructured":"Kahlem P, Sultan M, Herwig R, Steinfath M, Balzereit D, Eppens B, et al. (2004). Transcript level alterations reflect gene dosage effects across multiple tissues in a mouse model of down syndrome. Genome Res, 14:1258-67.","DOI":"10.1101\/gr.1951304"},{"key":"key-10.14336\/AD.2025.0189-29","doi-asserted-by":"crossref","unstructured":"Vilardell M, Rasche A, Thormann A, Maschke-Dutz E, Perez-Jurado LA, Lehrach H, et al. (2011). Meta-analysis of heterogeneous Down Syndrome data reveals consistent genome-wide dosage effects related to neurological processes. BMC Genomics, 12:229.","DOI":"10.1186\/1471-2164-12-229"},{"key":"key-10.14336\/AD.2025.0189-30","doi-asserted-by":"crossref","unstructured":"Antonarakis SE (2017). Down syndrome and the complexity of genome dosage imbalance. Nat Rev Genet, 18:147-163.","DOI":"10.1038\/nrg.2016.154"},{"key":"key-10.14336\/AD.2025.0189-31","doi-asserted-by":"crossref","unstructured":"Fullerton HJ, Ditelberg JS, Chen SF, Sarco DP, Chan PH, Epstein CJ, et al. (1998). Copper\/zinc superoxide dismutase transgenic brain accumulates hydrogen peroxide after perinatal hypoxia ischemia. Ann Neurol, 44:357-64.","DOI":"10.1002\/ana.410440311"},{"key":"key-10.14336\/AD.2025.0189-32","doi-asserted-by":"crossref","unstructured":"Manczak M, Mao P, Calkins MJ, Cornea A, Reddy AP, Murphy MP, et al. (2010). Mitochondria-targeted antioxidants protect against amyloid-beta toxicity in Alzheimer's disease neurons. J Alzheimers Dis, 20 Suppl 2:S609-31.","DOI":"10.3233\/JAD-2010-100564"},{"key":"key-10.14336\/AD.2025.0189-33","doi-asserted-by":"crossref","unstructured":"Bartley MG, Marquardt K, Kirchhof D, Wilkins HM, Patterson D and Linseman DA (2012). Overexpression of amyloid-beta protein precursor induces mitochondrial oxidative stress and activates the intrinsic apoptotic cascade. J Alzheimers Dis, 28:855-68.","DOI":"10.3233\/JAD-2011-111172"},{"key":"key-10.14336\/AD.2025.0189-34","doi-asserted-by":"crossref","unstructured":"Chang KT and Min KT (2005). Drosophila melanogaster homolog of Down syndrome critical region 1 is critical for mitochondrial function. Nat Neurosci, 8:1577-85.","DOI":"10.1038\/nn1564"},{"key":"key-10.14336\/AD.2025.0189-35","doi-asserted-by":"crossref","unstructured":"Sun X, Wu Y, Herculano B and Song W (2014). RCAN1 overexpression exacerbates calcium overloading-induced neuronal apoptosis. PLoS One, 9:e95471.","DOI":"10.1371\/journal.pone.0095471"},{"key":"key-10.14336\/AD.2025.0189-36","doi-asserted-by":"crossref","unstructured":"Walter C, Marada A, Suhm T, Ernsberger R, Muders V, Kucukkose C, et al. (2021). Global kinome profiling reveals DYRK1A as critical activator of the human mitochondrial import machinery. Nat Commun, 12:4284.","DOI":"10.1038\/s41467-021-24426-9"},{"key":"key-10.14336\/AD.2025.0189-37","doi-asserted-by":"crossref","unstructured":"Helguera P, Pelsman A, Pigino G, Wolvetang E, Head E and Busciglio J (2005). ets-2 promotes the activation of a mitochondrial death pathway in Down's syndrome neurons. J Neurosci, 25:2295-303.","DOI":"10.1523\/JNEUROSCI.5107-04.2005"},{"key":"key-10.14336\/AD.2025.0189-38","doi-asserted-by":"crossref","unstructured":"Qiu JJ, Liu YN, Ren ZR and Yan JB (2017). Dysfunctions of mitochondria in close association with strong perturbation of long noncoding RNAs expression in down syndrome. Int J Biochem Cell Biol, 92:115-120.","DOI":"10.1016\/j.biocel.2017.09.017"},{"key":"key-10.14336\/AD.2025.0189-39","doi-asserted-by":"crossref","unstructured":"Quinones-Lombrana A and Blanco JG (2015). Chromosome 21-derived hsa-miR-155-5p regulates mitochondrial biogenesis by targeting Mitochondrial Transcription Factor A (TFAM). Biochim Biophys Acta, 1852:1420-7.","DOI":"10.1016\/j.bbadis.2015.04.004"},{"key":"key-10.14336\/AD.2025.0189-40","doi-asserted-by":"crossref","unstructured":"Izzo A, Manco R, de Cristofaro T, Bonfiglio F, Cicatiello R, Mollo N, et al. (2017). Overexpression of Chromosome 21 miRNAs May Affect Mitochondrial Function in the Hearts of Down Syndrome Fetuses. Int J Genomics, 2017:8737649.","DOI":"10.1155\/2017\/8737649"},{"key":"key-10.14336\/AD.2025.0189-41","doi-asserted-by":"crossref","unstructured":"Markesbery WR and Lovell MA (2007). Damage to lipids, proteins, DNA, and RNA in mild cognitive impairment. Arch Neurol, 64:954-6.","DOI":"10.1001\/archneur.64.7.954"},{"key":"key-10.14336\/AD.2025.0189-42","doi-asserted-by":"crossref","unstructured":"Perluigi M, di Domenico F, Fiorini A, Cocciolo A, Giorgi A, Foppoli C, et al. (2011). Oxidative stress occurs early in Down syndrome pregnancy: A redox proteomics analysis of amniotic fluid. Proteomics Clin Appl, 5:167-78.","DOI":"10.1002\/prca.201000121"},{"key":"key-10.14336\/AD.2025.0189-43","doi-asserted-by":"crossref","unstructured":"Segal BH, Grimm MJ, Khan AN, Han W and Blackwell TS (2012). Regulation of innate immunity by NADPH oxidase. Free Radic Biol Med, 53:72-80.","DOI":"10.1016\/j.freeradbiomed.2012.04.022"},{"key":"key-10.14336\/AD.2025.0189-44","doi-asserted-by":"crossref","unstructured":"Sandalio LM, Rodriguez-Serrano M, Romero-Puertas MC and del Rio LA (2013). Role of peroxisomes as a source of reactive oxygen species (ROS) signaling molecules. Subcell Biochem, 69:231-55.","DOI":"10.1007\/978-94-007-6889-5_13"},{"key":"key-10.14336\/AD.2025.0189-45","doi-asserted-by":"crossref","unstructured":"Balaban RS, Nemoto S and Finkel T (2005). Mitochondria, oxidants, and aging. Cell, 120:483-95.","DOI":"10.1016\/j.cell.2005.02.001"},{"key":"key-10.14336\/AD.2025.0189-46","doi-asserted-by":"crossref","unstructured":"Busciglio J, Pelsman A, Wong C, Pigino G, Yuan M, Mori H, et al. (2002). Altered metabolism of the amyloid beta precursor protein is associated with mitochondrial dysfunction in Down's syndrome. Neuron, 33:677-88.","DOI":"10.1016\/S0896-6273(02)00604-9"},{"key":"key-10.14336\/AD.2025.0189-47","doi-asserted-by":"crossref","unstructured":"Di Domenico F, Pupo G, Mancuso C, Barone E, Paolini F, Arena A, et al. (2015). Bach1 overexpression in Down syndrome correlates with the alteration of the HO-1\/BVR-a system: insights for transition to Alzheimer's disease. J Alzheimers Dis, 44:1107-20.","DOI":"10.3233\/JAD-141254"},{"key":"key-10.14336\/AD.2025.0189-48","doi-asserted-by":"crossref","unstructured":"Esposito G, Imitola J, Lu J, De Filippis D, Scuderi C, Ganesh VS, et al. (2008). Genomic and functional profiling of human Down syndrome neural progenitors implicates S100B and aquaporin 4 in cell injury. Hum Mol Genet, 17:440-57.","DOI":"10.1093\/hmg\/ddm322"},{"key":"key-10.14336\/AD.2025.0189-49","doi-asserted-by":"crossref","unstructured":"Brooksbank BW and Balazs R (1984). Superoxide dismutase, glutathione peroxidase and lipoperoxidation in Down's syndrome fetal brain. Brain Res, 318:37-44.","DOI":"10.1016\/0165-3806(84)90060-9"},{"key":"key-10.14336\/AD.2025.0189-50","doi-asserted-by":"crossref","unstructured":"Sinha S (2005). Anti-oxidant gene expression imbalance, aging and Down syndrome. Life Sci, 76:1407-26.","DOI":"10.1016\/j.lfs.2004.10.026"},{"key":"key-10.14336\/AD.2025.0189-51","doi-asserted-by":"crossref","unstructured":"Di Carlo M, Giacomazza D, Picone P, Nuzzo D and San Biagio PL (2012). Are oxidative stress and mitochondrial dysfunction the key players in the neurodegenerative diseases? Free Radic Res, 46:1327-38.","DOI":"10.3109\/10715762.2012.714466"},{"key":"key-10.14336\/AD.2025.0189-52","doi-asserted-by":"crossref","unstructured":"Gimeno A, Garcia-Gimenez JL, Audi L, Toran N, Andaluz P, Dasi F, et al. (2014). Decreased cell proliferation and higher oxidative stress in fibroblasts from Down Syndrome fetuses. Preliminary study. Biochim Biophys Acta, 1842:116-25.","DOI":"10.1016\/j.bbadis.2013.10.014"},{"key":"key-10.14336\/AD.2025.0189-53","doi-asserted-by":"crossref","unstructured":"Garlet TR, Parisotto EB, de Medeiros Gda S, Pereira LC, Moreira EA, Dalmarco EM, et al. (2013). Systemic oxidative stress in children and teenagers with Down syndrome. Life Sci, 93:558-63.","DOI":"10.1016\/j.lfs.2013.08.017"},{"key":"key-10.14336\/AD.2025.0189-54","doi-asserted-by":"crossref","unstructured":"Sanchez-Font MF, Sebastia J, Sanfeliu C, Cristofol R, Marfany G and Gonzalez-Duarte R (2003). Peroxiredoxin 2 (PRDX2), an antioxidant enzyme, is under-expressed in Down syndrome fetal brains. Cell Mol Life Sci, 60:1513-23.","DOI":"10.1007\/s00018-003-3048-1"},{"key":"key-10.14336\/AD.2025.0189-55","doi-asserted-by":"crossref","unstructured":"Meguid NA, Dardir AA, El-Sayed EM, Ahmed HH, Hashish AF and Ezzat A (2010). Homocysteine and oxidative stress in Egyptian children with Down syndrome. Clin Biochem, 43:963-7.","DOI":"10.1016\/j.clinbiochem.2010.04.058"},{"key":"key-10.14336\/AD.2025.0189-56","doi-asserted-by":"crossref","unstructured":"Saghazadeh A, Mahmoudi M, Dehghani Ashkezari A, Oliaie Rezaie N and Rezaei N (2017). Systematic review and meta-analysis shows a specific micronutrient profile in people with Down Syndrome: Lower blood calcium, selenium and zinc, higher red blood cell copper and zinc, and higher salivary calcium and sodium. PLoS One, 12:e0175437.","DOI":"10.1371\/journal.pone.0175437"},{"key":"key-10.14336\/AD.2025.0189-57","doi-asserted-by":"crossref","unstructured":"Jackson CV, Holland AJ, Williams CA and Dickerson JW (1988). Vitamin E and Alzheimer's disease in subjects with Down's syndrome. J Ment Defic Res, 32( Pt 6):479-84.","DOI":"10.1111\/j.1365-2788.1988.tb01439.x"},{"key":"key-10.14336\/AD.2025.0189-58","doi-asserted-by":"crossref","unstructured":"Whittle N, Sartori SB, Dierssen M, Lubec G and Singewald N (2007). Fetal Down syndrome brains exhibit aberrant levels of neurotransmitters critical for normal brain development. Pediatrics, 120:e1465-71.","DOI":"10.1542\/peds.2006-3448"},{"key":"key-10.14336\/AD.2025.0189-59","doi-asserted-by":"crossref","unstructured":"Di Domenico F, Tramutola A and Butterfield DA (2017). Role of 4-hydroxy-2-nonenal (HNE) in the pathogenesis of alzheimer disease and other selected age-related neurodegenerative disorders. Free Radic Biol Med, 111:253-261.","DOI":"10.1016\/j.freeradbiomed.2016.10.490"},{"key":"key-10.14336\/AD.2025.0189-60","doi-asserted-by":"crossref","unstructured":"Busciglio J and Yankner BA (1995). Apoptosis and increased generation of reactive oxygen species in Down's syndrome neurons in vitro. Nature, 378:776-9.","DOI":"10.1038\/378776a0"},{"key":"key-10.14336\/AD.2025.0189-61","doi-asserted-by":"crossref","unstructured":"Di Domenico F, Coccia R, Cocciolo A, Murphy MP, Cenini G, Head E, et al. (2013). Impairment of proteostasis network in Down syndrome prior to the development of Alzheimer's disease neuropathology: redox proteomics analysis of human brain. Biochim Biophys Acta, 1832:1249-59.","DOI":"10.1016\/j.bbadis.2013.04.013"},{"key":"key-10.14336\/AD.2025.0189-62","doi-asserted-by":"crossref","unstructured":"Necchi D, Pinto A, Tillhon M, Dutto I, Serafini MM, Lanni C, et al. (2015). Defective DNA repair and increased chromatin binding of DNA repair factors in Down syndrome fibroblasts. Mutat Res, 780:15-23.","DOI":"10.1016\/j.mrfmmm.2015.07.009"},{"key":"key-10.14336\/AD.2025.0189-63","doi-asserted-by":"crossref","unstructured":"Morawiec Z, Janik K, Kowalski M, Stetkiewicz T, Szaflik J, Morawiec-Bajda A, et al. (2008). DNA damage and repair in children with Down's syndrome. Mutat Res, 637:118-23.","DOI":"10.1016\/j.mrfmmm.2007.07.010"},{"key":"key-10.14336\/AD.2025.0189-64","doi-asserted-by":"crossref","unstructured":"Nunomura A, Perry G, Hirai K, Aliev G, Takeda A, Chiba S, et al. (1999). Neuronal RNA oxidation in Alzheimer's disease and Down's syndrome. Ann N Y Acad Sci, 893:362-4.","DOI":"10.1111\/j.1749-6632.1999.tb07855.x"},{"key":"key-10.14336\/AD.2025.0189-65","doi-asserted-by":"crossref","unstructured":"Perluigi M and Butterfield DA (2012). Oxidative Stress and Down Syndrome: A Route toward Alzheimer-Like Dementia. Curr Gerontol Geriatr Res, 2012:724904.","DOI":"10.1155\/2012\/724904"},{"key":"key-10.14336\/AD.2025.0189-66","doi-asserted-by":"crossref","unstructured":"Zana M, Szecsenyi A, Czibula A, Bjelik A, Juhasz A, Rimanoczy A, et al. (2006). Age-dependent oxidative stress-induced DNA damage in Down's lymphocytes. Biochem Biophys Res Commun, 345:726-33.","DOI":"10.1016\/j.bbrc.2006.04.167"},{"key":"key-10.14336\/AD.2025.0189-67","doi-asserted-by":"crossref","unstructured":"Zamponi E and Helguera PR (2019). The Shape of Mitochondrial Dysfunction in Down Syndrome. Dev Neurobiol, 79:613-621.","DOI":"10.1002\/dneu.22673"},{"key":"key-10.14336\/AD.2025.0189-68","doi-asserted-by":"crossref","unstructured":"Piccoli C, Izzo A, Scrima R, Bonfiglio F, Manco R, Negri R, et al. (2013). Chronic pro-oxidative state and mitochondrial dysfunctions are more pronounced in fibroblasts from Down syndrome foeti with congenital heart defects. Hum Mol Genet, 22:1218-32.","DOI":"10.1093\/hmg\/dds529"},{"key":"key-10.14336\/AD.2025.0189-69","doi-asserted-by":"crossref","unstructured":"Singh D (2024). Revolutionizing cellular energy: The convergence of mitochondrial dynamics and delivery technologies. Mitochondrion, 76:101873.","DOI":"10.1016\/j.mito.2024.101873"},{"key":"key-10.14336\/AD.2025.0189-70","doi-asserted-by":"crossref","unstructured":"Izzo A, Nitti M, Mollo N, Paladino S, Procaccini C, Faicchia D, et al. (2017). Metformin restores the mitochondrial network and reverses mitochondrial dysfunction in Down syndrome cells. Hum Mol Genet, 26:1056-1069.","DOI":"10.1093\/hmg\/ddx016"},{"key":"key-10.14336\/AD.2025.0189-71","doi-asserted-by":"crossref","unstructured":"Valenti D, Rossi L, Marzulli D, Bellomo F, De Rasmo D, Signorile A, et al. (2017). Inhibition of Drp1-mediated mitochondrial fission improves mitochondrial dynamics and bioenergetics stimulating neurogenesis in hippocampal progenitor cells from a Down syndrome mouse model. Biochim Biophys Acta Mol Basis Dis, 1863:3117-3127.","DOI":"10.1016\/j.bbadis.2017.09.014"},{"key":"key-10.14336\/AD.2025.0189-72","doi-asserted-by":"crossref","unstructured":"Wong H, Levenga J, Cain P, Rothermel B, Klann E and Hoeffer C (2015). RCAN1 overexpression promotes age-dependent mitochondrial dysregulation related to neurodegeneration in Alzheimer's disease. Acta Neuropathol, 130:829-43.","DOI":"10.1007\/s00401-015-1499-8"},{"key":"key-10.14336\/AD.2025.0189-73","doi-asserted-by":"crossref","unstructured":"Predescu SA, Predescu DN, Knezevic I, Klein IK and Malik AB (2007). Intersectin-1s regulates the mitochondrial apoptotic pathway in endothelial cells. J Biol Chem, 282:17166-78.","DOI":"10.1074\/jbc.M608996200"},{"key":"key-10.14336\/AD.2025.0189-74","doi-asserted-by":"crossref","unstructured":"Iyer AM, van Scheppingen J, Milenkovic I, Anink JJ, Adle-Biassette H, Kovacs GG, et al. (2014). mTOR Hyperactivation in down syndrome hippocampus appears early during development. J Neuropathol Exp Neurol, 73:671-83.","DOI":"10.1097\/NEN.0000000000000083"},{"key":"key-10.14336\/AD.2025.0189-75","doi-asserted-by":"crossref","unstructured":"Wu W, Tian W, Hu Z, Chen G, Huang L, Li W, et al. (2014). ULK1 translocates to mitochondria and phosphorylates FUNDC1 to regulate mitophagy. EMBO Rep, 15:566-75.","DOI":"10.1002\/embr.201438501"},{"key":"key-10.14336\/AD.2025.0189-76","doi-asserted-by":"crossref","unstructured":"Montgomery MK and Turner N (2015). Mitochondrial dysfunction and insulin resistance: an update. Endocr Connect, 4:R1-R15.","DOI":"10.1530\/EC-14-0092"},{"key":"key-10.14336\/AD.2025.0189-77","doi-asserted-by":"crossref","unstructured":"Morton H, Kshirsagar S, Orlov E, Bunquin LE, Sawant N, Boleng L, et al. (2021). Defective mitophagy and synaptic degeneration in Alzheimer's disease: Focus on aging, mitochondria and synapse. Free Radic Biol Med, 172:652-667.","DOI":"10.1016\/j.freeradbiomed.2021.07.013"},{"key":"key-10.14336\/AD.2025.0189-78","doi-asserted-by":"crossref","unstructured":"Ganguly BB and Kadam NN (2022). Triplication of HSA21 on alterations in structure and function of mitochondria. Mitochondrion, 65:88-101.","DOI":"10.1016\/j.mito.2022.05.007"},{"key":"key-10.14336\/AD.2025.0189-79","doi-asserted-by":"crossref","unstructured":"Oliver DMA and Reddy PH (2019). Molecular Basis of Alzheimer's Disease: Focus on Mitochondria. J Alzheimers Dis, 72:S95-S116.","DOI":"10.3233\/JAD-190048"},{"key":"key-10.14336\/AD.2025.0189-80","doi-asserted-by":"crossref","unstructured":"Kim SH, Vlkolinsky R, Cairns N, Fountoulakis M and Lubec G (2001). The reduction of NADH ubiquinone oxidoreductase 24- and 75-kDa subunits in brains of patients with Down syndrome and Alzheimer's disease. Life Sci, 68:2741-50.","DOI":"10.1016\/S0024-3205(01)01074-8"},{"key":"key-10.14336\/AD.2025.0189-81","doi-asserted-by":"crossref","unstructured":"Valenti D, Tullo A, Caratozzolo MF, Merafina RS, Scartezzini P, Marra E, et al. (2010). Impairment of F1F0-ATPase, adenine nucleotide translocator and adenylate kinase causes mitochondrial energy deficit in human skin fibroblasts with chromosome 21 trisomy. Biochem J, 431:299-310.","DOI":"10.1042\/BJ20100581"},{"key":"key-10.14336\/AD.2025.0189-82","doi-asserted-by":"crossref","unstructured":"Murray A, Letourneau A, Canzonetta C, Stathaki E, Gimelli S, Sloan-Bena F, et al. (2015). Brief report: isogenic induced pluripotent stem cell lines from an adult with mosaic down syndrome model accelerated neuronal ageing and neurodegeneration. Stem Cells, 33:2077-84.","DOI":"10.1002\/stem.1968"},{"key":"key-10.14336\/AD.2025.0189-83","doi-asserted-by":"crossref","unstructured":"Coskun PE, Wyrembak J, Derbereva O, Melkonian G, Doran E, Lott IT, et al. (2010). Systemic mitochondrial dysfunction and the etiology of Alzheimer's disease and down syndrome dementia. J Alzheimers Dis, 20 Suppl 2:S293-310.","DOI":"10.3233\/JAD-2010-100351"},{"key":"key-10.14336\/AD.2025.0189-84","doi-asserted-by":"crossref","unstructured":"Liu Y, Borel C, Li L, Muller T, Williams EG, Germain PL, et al. (2017). Systematic proteome and proteostasis profiling in human Trisomy 21 fibroblast cells. Nat Commun, 8:1212.","DOI":"10.1038\/s41467-017-01422-6"},{"key":"key-10.14336\/AD.2025.0189-85","doi-asserted-by":"crossref","unstructured":"Gleyzer N, Vercauteren K and Scarpulla RC (2005). Control of mitochondrial transcription specificity factors (TFB1M and TFB2M) by nuclear respiratory factors (NRF-1 and NRF-2) and PGC-1 family coactivators. Mol Cell Biol, 25:1354-66.","DOI":"10.1128\/MCB.25.4.1354-1366.2005"},{"key":"key-10.14336\/AD.2025.0189-86","doi-asserted-by":"crossref","unstructured":"Ventura-Clapier R, Garnier A and Veksler V (2008). Transcriptional control of mitochondrial biogenesis: the central role of PGC-1alpha. Cardiovasc Res, 79:208-17.","DOI":"10.1093\/cvr\/cvn098"},{"key":"key-10.14336\/AD.2025.0189-87","doi-asserted-by":"crossref","unstructured":"Liu F, Liang Z, Wegiel J, Hwang YW, Iqbal K, Grundke-Iqbal I, et al. (2008). Overexpression of Dyrk1A contributes to neurofibrillary degeneration in Down syndrome. FASEB J, 22:3224-33.","DOI":"10.1096\/fj.07-104539"},{"key":"key-10.14336\/AD.2025.0189-88","doi-asserted-by":"crossref","unstructured":"Lee S, Bang SM, Hong YK, Lee JH, Jeong H, Park SH, et al. (2016). The calcineurin inhibitor Sarah (Nebula) exacerbates Abeta42 phenotypes in a Drosophila model of Alzheimer's disease. Dis Model Mech, 9:295-306.","DOI":"10.1242\/dmm.018069"},{"key":"key-10.14336\/AD.2025.0189-89","doi-asserted-by":"crossref","unstructured":"Ermak G, Sojitra S, Yin F, Cadenas E, Cuervo AM and Davies KJ (2012). Chronic expression of RCAN1-1L protein induces mitochondrial autophagy and metabolic shift from oxidative phosphorylation to glycolysis in neuronal cells. J Biol Chem, 287:14088-98.","DOI":"10.1074\/jbc.M111.305342"},{"key":"key-10.14336\/AD.2025.0189-90","doi-asserted-by":"crossref","unstructured":"Izzo A, Manco R, Bonfiglio F, Cali G, De Cristofaro T, Patergnani S, et al. (2014). NRIP1\/RIP140 siRNA-mediated attenuation counteracts mitochondrial dysfunction in Down syndrome. Hum Mol Genet, 23:4406-19.","DOI":"10.1093\/hmg\/ddu157"},{"key":"key-10.14336\/AD.2025.0189-91","doi-asserted-by":"crossref","unstructured":"Rytinki MM and Palvimo JJ (2008). SUMOylation modulates the transcription repressor function of RIP140. J Biol Chem, 283:11586-95.","DOI":"10.1074\/jbc.M709359200"},{"key":"key-10.14336\/AD.2025.0189-92","doi-asserted-by":"crossref","unstructured":"Rytinki MM and Palvimo JJ (2009). SUMOylation attenuates the function of PGC-1alpha. J Biol Chem, 284:26184-93.","DOI":"10.1074\/jbc.M109.038943"},{"key":"key-10.14336\/AD.2025.0189-93","doi-asserted-by":"crossref","unstructured":"Kanzleiter T, Rath M, Penkov D, Puchkov D, Schulz N, Blasi F, et al. (2014). Pknox1\/Prep1 regulates mitochondrial oxidative phosphorylation components in skeletal muscle. Mol Cell Biol, 34:290-8.","DOI":"10.1128\/MCB.01232-13"},{"key":"key-10.14336\/AD.2025.0189-94","doi-asserted-by":"crossref","unstructured":"Padilla J and Lee J (2021). A Novel Therapeutic Target, BACH1, Regulates Cancer Metabolism. Cells, 10.","DOI":"10.3390\/cells10030634"},{"key":"key-10.14336\/AD.2025.0189-95","doi-asserted-by":"crossref","unstructured":"Bush A and Beail N (2004). Risk Factors for Dementia in People With Down Syndrome: Issues in Assessment and Diagnosis. American Journal on Mental Retardation, 109.","DOI":"10.1352\/0895-8017(2004)109<83:RFFDIP>2.0.CO;2"},{"key":"key-10.14336\/AD.2025.0189-96","doi-asserted-by":"crossref","unstructured":"Zana M, Janka Z and Kalman J (2007). Oxidative stress: a bridge between Down's syndrome and Alzheimer's disease. Neurobiol Aging, 28:648-76.","DOI":"10.1016\/j.neurobiolaging.2006.03.008"},{"key":"key-10.14336\/AD.2025.0189-97","doi-asserted-by":"crossref","unstructured":"Fortea J, Zaman SH, Hartley S, Rafii MS, Head E and Carmona-Iragui M (2021). Alzheimer's disease associated with Down syndrome: a genetic form of dementia. Lancet Neurol, 20:930-942.","DOI":"10.1016\/S1474-4422(21)00245-3"},{"key":"key-10.14336\/AD.2025.0189-98","doi-asserted-by":"crossref","unstructured":"Lott IT and Head E (2019). Dementia in Down syndrome: unique insights for Alzheimer disease research. Nat Rev Neurol, 15:135-147.","DOI":"10.1038\/s41582-018-0132-6"},{"key":"key-10.14336\/AD.2025.0189-99","doi-asserted-by":"crossref","unstructured":"Zhu X, Raina AK, Perry G and Smith MA (2004). Alzheimer's disease: the two-hit hypothesis. Lancet Neurol, 3:219-26.","DOI":"10.1016\/S1474-4422(04)00707-0"},{"key":"key-10.14336\/AD.2025.0189-100","doi-asserted-by":"crossref","unstructured":"Zhu X, Lee HG, Perry G and Smith MA (2007). Alzheimer disease, the two-hit hypothesis: an update. Biochim Biophys Acta, 1772:494-502.","DOI":"10.1016\/j.bbadis.2006.10.014"},{"key":"key-10.14336\/AD.2025.0189-101","doi-asserted-by":"crossref","unstructured":"Elangovan A, Babu HWS, Iyer M, Gopalakrishnan AV and Vellingiri B (2023). Untangle the mystery behind DS-associated AD - Is APP the main protagonist? Ageing Res Rev, 87:101930.","DOI":"10.1016\/j.arr.2023.101930"},{"key":"key-10.14336\/AD.2025.0189-102","doi-asserted-by":"crossref","unstructured":"Mucke L and Selkoe DJ (2012). Neurotoxicity of amyloid beta-protein: synaptic and network dysfunction. Cold Spring Harb Perspect Med, 2:a006338.","DOI":"10.1101\/cshperspect.a006338"},{"key":"key-10.14336\/AD.2025.0189-103","doi-asserted-by":"crossref","unstructured":"John A and Reddy PH (2021). Synaptic basis of Alzheimer's disease: Focus on synaptic amyloid beta, P-tau and mitochondria. Ageing Res Rev, 65:101208.","DOI":"10.1016\/j.arr.2020.101208"},{"key":"key-10.14336\/AD.2025.0189-104","doi-asserted-by":"crossref","unstructured":"Mori C, Spooner ET, Wisniewski KE, Wisniewski TM, Yamaguchi H, Saido TC, et al. (2009). Intraneuronal A\u03b242 accumulation in Down syndrome brain. Amyloid, 9:88-102.","DOI":"10.3109\/13506120208995241"},{"key":"key-10.14336\/AD.2025.0189-105","doi-asserted-by":"crossref","unstructured":"Thirumalai S, Livesey FJ, Patani R and Hung C (2025). APP antisense oligonucleotides are effective in rescuing mitochondrial phenotypes in human iPSC-derived trisomy 21 astrocytes. Alzheimers Dement, 21:e14560.","DOI":"10.1002\/alz.14560"},{"key":"key-10.14336\/AD.2025.0189-106","doi-asserted-by":"crossref","unstructured":"Ermak G, Pritchard MA, Dronjak S, Niu B and Davies KJ (2011). Do RCAN1 proteins link chronic stress with neurodegeneration? FASEB J, 25:3306-11.","DOI":"10.1096\/fj.11-185728"},{"key":"key-10.14336\/AD.2025.0189-107","doi-asserted-by":"crossref","unstructured":"Lloret A, Badia MC, Giraldo E, Ermak G, Alonso MD, Pallardo FV, et al. (2011). Amyloid-beta toxicity and tau hyperphosphorylation are linked via RCAN1 in Alzheimer's disease. J Alzheimers Dis, 27:701-9.","DOI":"10.3233\/JAD-2011-110890"},{"key":"key-10.14336\/AD.2025.0189-108","doi-asserted-by":"crossref","unstructured":"Royston MC, McKenzie JE, Gentleman SM, Sheng JG, Mann DM, Griffin WS, et al. (1999). Overexpression of s100beta in Down's syndrome: correlation with patient age and with beta-amyloid deposition. Neuropathol Appl Neurobiol, 25:387-93.","DOI":"10.1046\/j.1365-2990.1999.00196.x"},{"key":"key-10.14336\/AD.2025.0189-109","doi-asserted-by":"crossref","unstructured":"Ryoo SR, Jeong HK, Radnaabazar C, Yoo JJ, Cho HJ, Lee HW, et al. (2007). DYRK1A-mediated hyperphosphorylation of Tau. A functional link between Down syndrome and Alzheimer disease. J Biol Chem, 282:34850-7.","DOI":"10.1074\/jbc.M707358200"},{"key":"key-10.14336\/AD.2025.0189-110","doi-asserted-by":"crossref","unstructured":"Hayflick L and Moorhead PS (1961). The serial cultivation of human diploid cell strains. Exp Cell Res, 25:585-621.","DOI":"10.1016\/0014-4827(61)90192-6"},{"key":"key-10.14336\/AD.2025.0189-111","doi-asserted-by":"crossref","unstructured":"Munoz-Espin D and Serrano M (2014). Cellular senescence: from physiology to pathology. Nat Rev Mol Cell Biol, 15:482-96.","DOI":"10.1038\/nrm3823"},{"key":"key-10.14336\/AD.2025.0189-112","doi-asserted-by":"crossref","unstructured":"Lopez-Otin C, Blasco MA, Partridge L, Serrano M and Kroemer G (2013). The hallmarks of aging. Cell, 153:1194-217.","DOI":"10.1016\/j.cell.2013.05.039"},{"key":"key-10.14336\/AD.2025.0189-113","doi-asserted-by":"crossref","unstructured":"Jurk D, Wang C, Miwa S, Maddick M, Korolchuk V, Tsolou A, et al. (2012). Postmitotic neurons develop a p21-dependent senescence-like phenotype driven by a DNA damage response. Aging Cell, 11:996-1004.","DOI":"10.1111\/j.1474-9726.2012.00870.x"},{"key":"key-10.14336\/AD.2025.0189-114","doi-asserted-by":"crossref","unstructured":"Musi N, Valentine JM, Sickora KR, Baeuerle E, Thompson CS, Shen Q, et al. (2018). Tau protein aggregation is associated with cellular senescence in the brain. Aging Cell, 17:e12840.","DOI":"10.1111\/acel.12840"},{"key":"key-10.14336\/AD.2025.0189-115","doi-asserted-by":"crossref","unstructured":"Kalanj-Bognar S, Rundek T, Furac I, Demarin V and Cosovic C (2002). Leukocyte lysosomal enzymes in Alzheimer's disease and Down's syndrome. J Gerontol A Biol Sci Med Sci, 57:B16-21.","DOI":"10.1093\/gerona\/57.1.B16"},{"key":"key-10.14336\/AD.2025.0189-116","doi-asserted-by":"crossref","unstructured":"Rueda N, Vidal V, Garcia-Cerro S, Narcis JO, Llorens-Martin M, Corrales A, et al. (2018). Anti-IL17 treatment ameliorates Down syndrome phenotypes in mice. Brain Behav Immun, 73:235-251.","DOI":"10.1016\/j.bbi.2018.05.008"},{"key":"key-10.14336\/AD.2025.0189-117","doi-asserted-by":"crossref","unstructured":"Ahmed AA, Smoczer C, Pace B, Patterson D and Cress Cabelof D (2018). Loss of DNA polymerase beta induces cellular senescence. Environ Mol Mutagen, 59:603-612.","DOI":"10.1002\/em.22206"},{"key":"key-10.14336\/AD.2025.0189-118","doi-asserted-by":"crossref","unstructured":"Meharena HS, Marco A, Dileep V, Lockshin ER, Akatsu GY, Mullahoo J, et al. (2022). Down-syndrome-induced senescence disrupts the nuclear architecture of neural progenitors. Cell Stem Cell, 29:116-130 e7.","DOI":"10.1016\/j.stem.2021.12.002"},{"key":"key-10.14336\/AD.2025.0189-119","doi-asserted-by":"crossref","unstructured":"Adorno M, Sikandar S, Mitra SS, Kuo A, Nicolis Di Robilant B, Haro-Acosta V, et al. (2013). Usp16 contributes to somatic stem-cell defects in Down's syndrome. Nature, 501:380-4.","DOI":"10.1038\/nature12530"},{"key":"key-10.14336\/AD.2025.0189-120","doi-asserted-by":"crossref","unstructured":"Pawlikowski B, Betta ND, Elston T, Williams DA and Olwin BB (2018). Muscle stem cell dysfunction impairs muscle regeneration in a mouse model of Down syndrome. Sci Rep, 8:4309.","DOI":"10.1038\/s41598-018-22342-5"},{"key":"key-10.14336\/AD.2025.0189-121","doi-asserted-by":"crossref","unstructured":"Contestabile A, Fila T, Ceccarelli C, Bonasoni P, Bonapace L, Santini D, et al. (2007). Cell cycle alteration and decreased cell proliferation in the hippocampal dentate gyrus and in the neocortical germinal matrix of fetuses with Down syndrome and in Ts65Dn mice. Hippocampus, 17:665-78.","DOI":"10.1002\/hipo.20308"},{"key":"key-10.14336\/AD.2025.0189-122","doi-asserted-by":"crossref","unstructured":"Sukenik-Halevy R, Biron-Shental T, Sharony R, Fejgin MD and Amiel A (2011). Telomeres in trisomy 21 amniocytes. Cytogenet Genome Res, 135:12-8.","DOI":"10.1159\/000329714"},{"key":"key-10.14336\/AD.2025.0189-123","doi-asserted-by":"crossref","unstructured":"Amiel A, Fejgin MD, Liberman M, Sharon Y, Kidron D and Biron-Shental T (2013). Senescence in amniocytes and placentas from trisomy 21 pregnancies. J Matern Fetal Neonatal Med, 26:1086-9.","DOI":"10.3109\/14767058.2013.768982"},{"key":"key-10.14336\/AD.2025.0189-124","doi-asserted-by":"crossref","unstructured":"Rodriguez-Sureda V, Vilches A, Sanchez O, Audi L and Dominguez C (2015). Intracellular oxidant activity, antioxidant enzyme defense system, and cell senescence in fibroblasts with trisomy 21. Oxid Med Cell Longev, 2015:509241.","DOI":"10.1155\/2015\/509241"},{"key":"key-10.14336\/AD.2025.0189-125","doi-asserted-by":"crossref","unstructured":"Lockrow J, Prakasam A, Huang P, Bimonte-Nelson H, Sambamurti K and Granholm AC (2009). Cholinergic degeneration and memory loss delayed by vitamin E in a Down syndrome mouse model. Exp Neurol, 216:278-89.","DOI":"10.1016\/j.expneurol.2008.11.021"},{"key":"key-10.14336\/AD.2025.0189-126","doi-asserted-by":"crossref","unstructured":"Sano M, Aisen PS, Andrews HF, Tsai WY, Lai F, Dalton AJ, et al. (2016). Vitamin E in aging persons with Down syndrome: A randomized, placebo-controlled clinical trial. Neurology, 86:2071-6.","DOI":"10.1212\/WNL.0000000000002714"},{"key":"key-10.14336\/AD.2025.0189-127","doi-asserted-by":"crossref","unstructured":"Lee P and Ulatowski LM (2019). Vitamin E: Mechanism of transport and regulation in the CNS. IUBMB Life, 71:424-429.","DOI":"10.1002\/iub.1993"},{"key":"key-10.14336\/AD.2025.0189-128","doi-asserted-by":"crossref","unstructured":"Parisotto EB, Giaretta AG, Zamoner A, Moreira EA, Frode TS, Pedrosa RC, et al. (2015). Persistence of the benefit of an antioxidant therapy in children and teenagers with Down syndrome. Res Dev Disabil, 45-46:14-20.","DOI":"10.1016\/j.ridd.2015.07.010"},{"key":"key-10.14336\/AD.2025.0189-129","doi-asserted-by":"crossref","unstructured":"Parisotto EB, Garlet TR, Cavalli VL, Zamoner A, da Rosa JS, Bastos J, et al. (2014). Antioxidant intervention attenuates oxidative stress in children and teenagers with Down syndrome. Res Dev Disabil, 35:1228-36.","DOI":"10.1016\/j.ridd.2014.03.013"},{"key":"key-10.14336\/AD.2025.0189-130","doi-asserted-by":"crossref","unstructured":"Tiano L, Padella L, Santoro L, Carnevali P, Principi F, Bruge F, et al. (2012). Prolonged coenzyme Q10 treatment in Down syndrome patients: effect on DNA oxidation. Neurobiol Aging, 33:626 e1-8.","DOI":"10.1016\/j.neurobiolaging.2011.03.025"},{"key":"key-10.14336\/AD.2025.0189-131","doi-asserted-by":"crossref","unstructured":"Larsen EL, Padella L, Bergholdt HKM, Henriksen T, Santoro L, Gabrielli O, et al. (2018). The effect of long-term treatment with coenzyme Q10 on nucleic acid modifications by oxidation in children with Down syndrome. Neurobiol Aging, 67:159-161.","DOI":"10.1016\/j.neurobiolaging.2018.03.001"},{"key":"key-10.14336\/AD.2025.0189-132","doi-asserted-by":"crossref","unstructured":"Santos RA, Costa LH, Linhares RC, Pradella-Hallinan M, Coelho FMS and Oliveira GDP (2022). Sleep disorders in Down syndrome: a systematic review. Arq Neuropsiquiatr, 80:424-443.","DOI":"10.1590\/0004-282x-anp-2021-0242"},{"key":"key-10.14336\/AD.2025.0189-133","doi-asserted-by":"crossref","unstructured":"Uberos J, Romero J, Molina-Carballo A and Munoz-Hoyos A (2010). Melatonin and elimination of kynurenines in children with Down's syndrome. J Pediatr Endocrinol Metab, 23:277-82.","DOI":"10.1515\/JPEM.2010.23.3.277"},{"key":"key-10.14336\/AD.2025.0189-134","doi-asserted-by":"crossref","unstructured":"Parisotto EB, Vidal V, Garcia-Cerro S, Lantigua S, Wilhelm Filho D, Sanchez-Barcelo EJ, et al. (2016). Chronic Melatonin Administration Reduced Oxidative Damage and Cellular Senescence in the Hippocampus of a Mouse Model of Down Syndrome. Neurochem Res, 41:2904-2913.","DOI":"10.1007\/s11064-016-2008-8"},{"key":"key-10.14336\/AD.2025.0189-135","doi-asserted-by":"crossref","unstructured":"Corrales A, Martinez P, Garcia S, Vidal V, Garcia E, Florez J, et al. (2013). Long-term oral administration of melatonin improves spatial learning and memory and protects against cholinergic degeneration in middle-aged Ts65Dn mice, a model of Down syndrome. J Pineal Res, 54:346-58.","DOI":"10.1111\/jpi.12037"},{"key":"key-10.14336\/AD.2025.0189-136","doi-asserted-by":"crossref","unstructured":"Vacca RA, Valenti D, Caccamese S, Daglia M, Braidy N and Nabavi SM (2016). Plant polyphenols as natural drugs for the management of Down syndrome and related disorders. Neurosci Biobehav Rev, 71:865-877.","DOI":"10.1016\/j.neubiorev.2016.10.023"},{"key":"key-10.14336\/AD.2025.0189-137","doi-asserted-by":"crossref","unstructured":"Schroeder EK, Kelsey NA, Doyle J, Breed E, Bouchard RJ, Loucks FA, et al. (2009). Green tea epigallocatechin 3-gallate accumulates in mitochondria and displays a selective antiapoptotic effect against inducers of mitochondrial oxidative stress in neurons. Antioxid Redox Signal, 11:469-80.","DOI":"10.1089\/ars.2008.2215"},{"key":"key-10.14336\/AD.2025.0189-138","doi-asserted-by":"crossref","unstructured":"Valenti D, De Rasmo D, Signorile A, Rossi L, de Bari L, Scala I, et al. (2013). Epigallocatechin-3-gallate prevents oxidative phosphorylation deficit and promotes mitochondrial biogenesis in human cells from subjects with Down's syndrome. Biochim Biophys Acta, 1832:542-52.","DOI":"10.1016\/j.bbadis.2012.12.011"},{"key":"key-10.14336\/AD.2025.0189-139","doi-asserted-by":"crossref","unstructured":"de la Torre R, de Sola S, Hernandez G, Farre M, Pujol J, Rodriguez J, et al. (2016). Safety and efficacy of cognitive training plus epigallocatechin-3-gallate in young adults with Down's syndrome (TESDAD): a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet Neurol, 15:801-810.","DOI":"10.1016\/S1474-4422(16)30034-5"},{"key":"key-10.14336\/AD.2025.0189-140","doi-asserted-by":"crossref","unstructured":"Valenti D, de Bari L, de Rasmo D, Signorile A, Henrion-Caude A, Contestabile A, et al. (2016). The polyphenols resveratrol and epigallocatechin-3-gallate restore the severe impairment of mitochondria in hippocampal progenitor cells from a Down syndrome mouse model. Biochim Biophys Acta, 1862:1093-104.","DOI":"10.1016\/j.bbadis.2016.03.003"},{"key":"key-10.14336\/AD.2025.0189-141","doi-asserted-by":"crossref","unstructured":"Brasnyo P, Molnar GA, Mohas M, Marko L, Laczy B, Cseh J, et al. (2011). Resveratrol improves insulin sensitivity, reduces oxidative stress and activates the Akt pathway in type 2 diabetic patients. Br J Nutr, 106:383-9.","DOI":"10.1017\/S0007114511000316"},{"key":"key-10.14336\/AD.2025.0189-142","doi-asserted-by":"crossref","unstructured":"Mollo N, Cicatiello R, Aurilia M, Scognamiglio R, Genesio R, Charalambous M, et al. (2020). Targeting Mitochondrial Network Architecture in Down Syndrome and Aging. Int J Mol Sci, 21.","DOI":"10.3390\/ijms21093134"},{"key":"key-10.14336\/AD.2025.0189-143","doi-asserted-by":"crossref","unstructured":"Wang X, Su B, Lee HG, Li X, Perry G, Smith MA, et al. (2009). Impaired balance of mitochondrial fission and fusion in Alzheimer's disease. J Neurosci, 29:9090-103.","DOI":"10.1523\/JNEUROSCI.1357-09.2009"},{"key":"key-10.14336\/AD.2025.0189-144","doi-asserted-by":"crossref","unstructured":"Hall AR, Burke N, Dongworth RK and Hausenloy DJ (2014). Mitochondrial fusion and fission proteins: novel therapeutic targets for combating cardiovascular disease. Br J Pharmacol, 171:1890-906.","DOI":"10.1111\/bph.12516"},{"key":"key-10.14336\/AD.2025.0189-145","doi-asserted-by":"crossref","unstructured":"Mollo N, Nitti M, Zerillo L, Faicchia D, Micillo T, Accarino R, et al. (2019). Pioglitazone Improves Mitochondrial Organization and Bioenergetics in Down Syndrome Cells. Front Genet, 10:606.","DOI":"10.3389\/fgene.2019.00606"},{"key":"key-10.14336\/AD.2025.0189-146","doi-asserted-by":"crossref","unstructured":"Chen Y, Chen J, Sun X, Shi X, Wang L, Huang L, et al. (2018). Evaluation of the neuroprotective effect of EGCG: a potential mechanism of mitochondrial dysfunction and mitochondrial dynamics after subarachnoid hemorrhage. Food Funct, 9:6349-6359.","DOI":"10.1039\/C8FO01497C"},{"key":"key-10.14336\/AD.2025.0189-147","doi-asserted-by":"crossref","unstructured":"Lamming DW (2016). Inhibition of the Mechanistic Target of Rapamycin (mTOR)-Rapamycin and Beyond. Cold Spring Harb Perspect Med, 6.","DOI":"10.1101\/cshperspect.a025924"},{"key":"key-10.14336\/AD.2025.0189-148","doi-asserted-by":"crossref","unstructured":"Di Domenico F, Tramutola A, Barone E, Lanzillotta C, Defever O, Arena A, et al. (2019). Restoration of aberrant mTOR signaling by intranasal rapamycin reduces oxidative damage: Focus on HNE-modified proteins in a mouse model of down syndrome. Redox Biol, 23:101162.","DOI":"10.1016\/j.redox.2019.101162"},{"key":"key-10.14336\/AD.2025.0189-149","doi-asserted-by":"crossref","unstructured":"Pradeepkiran JA and Reddy PH (2020). Defective mitophagy in Alzheimer's disease. Ageing Res Rev, 64:101191.","DOI":"10.1016\/j.arr.2020.101191"},{"key":"key-10.14336\/AD.2025.0189-150","doi-asserted-by":"crossref","unstructured":"Pradeepkiran JA, Baig J, Seman A and Reddy PH (2024). Mitochondria in Aging and Alzheimer's Disease: Focus on Mitophagy. Neuroscientist, 30:440-457.","DOI":"10.1177\/10738584221139761"},{"key":"key-10.14336\/AD.2025.0189-151","doi-asserted-by":"crossref","unstructured":"Andreux PA, Blanco-Bose W, Ryu D, Burdet F, Ibberson M, Aebischer P, et al. (2019). The mitophagy activator urolithin A is safe and induces a molecular signature of improved mitochondrial and cellular health in humans. Nat Metab, 1:595-603.","DOI":"10.1038\/s42255-019-0073-4"},{"key":"key-10.14336\/AD.2025.0189-152","doi-asserted-by":"crossref","unstructured":"Tran M and Reddy PH (2020). Defective Autophagy and Mitophagy in Aging and Alzheimer's Disease. Front Neurosci, 14:612757.","DOI":"10.3389\/fnins.2020.612757"},{"key":"key-10.14336\/AD.2025.0189-153","doi-asserted-by":"crossref","unstructured":"Kirkland JL and Tchkonia T (2020). Senolytic drugs: from discovery to translation. J Intern Med, 288:518-536.","DOI":"10.1111\/joim.13141"},{"key":"key-10.14336\/AD.2025.0189-154","doi-asserted-by":"crossref","unstructured":"Roberts AW, Davids MS, Pagel JM, Kahl BS, Puvvada SD, Gerecitano JF, et al. (2016). Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia. N Engl J Med, 374:311-22.","DOI":"10.1056\/NEJMoa1513257"},{"key":"key-10.14336\/AD.2025.0189-155","unstructured":"Vacurova E, Vlachova E, Stursa J, Bohacova K, Havrlantova T, Skop V, et al. (2025). Targeting Mitochondrial Integrity as a New Senolytic Strategy. Aging Dis."},{"key":"key-10.14336\/AD.2025.0189-156","doi-asserted-by":"crossref","unstructured":"Iulita MF, Bejanin A, Vilaplana E, Carmona-Iragui M, Benejam B, Videla L, et al. (2023). Association of biological sex with clinical outcomes and biomarkers of Alzheimer's disease in adults with Down syndrome. Brain Commun, 5:fcad074.","DOI":"10.1093\/braincomms\/fcad074"},{"key":"key-10.14336\/AD.2025.0189-157","doi-asserted-by":"crossref","unstructured":"Del Hoyo Soriano L, Wagemann O, Bejanin A, Levin J and Fortea J (2025). Sex-related differences in genetically determined Alzheimer's disease. Front Aging Neurosci, 17:1522434.","DOI":"10.3389\/fnagi.2025.1522434"},{"key":"key-10.14336\/AD.2025.0189-158","doi-asserted-by":"crossref","unstructured":"Zhu X, Lee HG, Casadesus G, Avila J, Drew K, Perry G, et al. (2005). Oxidative imbalance in Alzheimer's disease. Mol Neurobiol, 31:205-17.","DOI":"10.1385\/MN:31:1-3:205"},{"key":"key-10.14336\/AD.2025.0189-159","doi-asserted-by":"crossref","unstructured":"Ludtmann MHR and Abramov AY (2018). Mitochondrial calcium imbalance in Parkinson's disease. Neurosci Lett, 663:86-90.","DOI":"10.1016\/j.neulet.2017.08.044"},{"key":"key-10.14336\/AD.2025.0189-160","doi-asserted-by":"crossref","unstructured":"D'Egidio F, Castelli V, Cimini A and d'Angelo M (2023). Cell Rearrangement and Oxidant\/Antioxidant Imbalance in Huntington's Disease. Antioxidants(Basel), 12.","DOI":"10.3390\/antiox12030571"},{"key":"key-10.14336\/AD.2025.0189-161","doi-asserted-by":"crossref","unstructured":"Zuo X, Zhou J, Li Y, Wu K, Chen Z, Luo Z, et al. (2021). TDP-43 aggregation induced by oxidative stress causes global mitochondrial imbalance in ALS. Nat Struct Mol Biol, 28:132-142.","DOI":"10.1038\/s41594-020-00537-7"}],"container-title":["Aging and disease"],"original-title":[],"language":"en","deposited":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T23:21:09Z","timestamp":1744154469000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.aginganddisease.org\/EN\/10.14336\/AD.2025.0189"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":161,"URL":"https:\/\/doi.org\/10.14336\/ad.2025.0189","relation":{},"ISSN":["2152-5250"],"issn-type":[{"value":"2152-5250","type":"print"}],"subject":[],"published":{"date-parts":[[2025]]}}}